共 55 条
[1]
Choy EH(2001)Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 907-916
[2]
Panayi GS(2002)Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials Ann Rheum Dis. 61 ii70-3-45
[3]
Rau R(2003)Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 35-516
[4]
Weinblatt ME(2004)Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis 63 508-1199
[5]
Keystone EC(2007)Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Rheumatology (Oxford). 6 1191-982
[6]
Furst DE(2016)The changing landscape of biosimilars in rheumatology Ann Rheum Dis 75 974-218
[7]
Moreland LW(2017)Treatment outcomes with biosimilars: be aware of the nocebo effect Rheumatol Ther. 4 209-21
[8]
Weisman MH(2017)Review of biosimilars of adalimumab J Assoc Physicians India 65 15-1168
[9]
Birbara CA(2017)The road from development to approval: evaluating the body of evidence to confirm biosimilarity Rheumatology (Oxford). 56 iv4-13-625
[10]
van de Putte LB(2016)A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis Int J Rheum Dis 19 1157-21